- In August 2021, the FDA approved Merck’s WELIREG™ (belzutifan), a Hypoxia-Inducible Factor-2 Alpha (HIF-2) inhibitor, for treating patients with specific tumors associated with Von Hippel-Lindau (VHL) disease. This significant approval highlights the therapeutic potential of targeting hypoxia-related pathways in cancer treatment. By addressing these tumors, WELIREG™ offers a new treatment option for patients suffering from this rare genetic condition
- In November 2021, Diffusion Pharmaceuticals Inc., a biopharmaceutical firm, announced the successful dosing of the first participants in its Altitude Trial. This trial aims to evaluate the company’s lead product candidate, Trans Sodium Crocetinate (TSC), by exposing healthy volunteers to progressively increasing levels of physical exertion under hypoxic and hypobaric conditions. The study is designed to assess TSC's effectiveness in enhancing oxygen delivery during challenging environments, potentially offering new insights into hypoxia management
- In May 2022, Max Ventilator introduced multifunctional non-invasive ventilators equipped with built-in oxygen therapy and a humidifier. These advanced devices are designed to provide comprehensive respiratory support, ensuring optimal oxygen delivery and comfort for patients. By integrating these features, Max Ventilator enhances the effectiveness of treatment while improving patient experience during respiratory care
- In April 2022, CAIRE launched the LifeStyle portable oxygen concentrator, significantly improving the quality of life for oxygen users worldwide. This innovative device offers greater mobility and convenience, allowing individuals with respiratory conditions to engage more fully in daily activities. By providing a reliable source of oxygen therapy in a compact and portable design, the LifeStyle concentrator empowers users to maintain their independence and enjoy a better overall lifestyle
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Hypoxic Hypoxia, Anaemic Hypoxia, Stagnant Hypoxia, and Histotoxic Hypoxia), Disease Type (Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Bronchitis, Pneumonia, Sleep Apnoea, Pneumothorax, Asthma, and Others), End User (Hospitals, Specialty Clinics, Research Centres, and Others), Distribution Channel (Direct and Indirect) – Industry Trends and Forecast to 2031
.
The Global Hypoxia Market size was valued at USD 152.30 USD Million in 2023.
The Global Hypoxia Market is projected to grow at a CAGR of 7.5% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
